Revolution Medicines (RVMD) Total Current Liabilities (2019 - 2026)
Revolution Medicines (RVMD) posted quarterly Total Current Liabilities of $289.6 million for Q1 2026, up 82.6% year-over-year from $158.6 million in Q1 2025, and little changed quarter-over-quarter from $290.4 million in Q4 2025.
Revolution Medicines (RVMD) Total Current Liabilities (2019 - 2026) Analysis & Trends
Revolution Medicines' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $289.6 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 82.6% year-over-year to $289.6 million; the TTM figure through Mar 2026 stood at $289.6 million (up 82.6% YoY), while the FY2025 annual figure was $290.4 million, up 77.18% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $289.6 million, roughly flat from $290.4 million in the prior quarter.
- The five-year high for Total Current Liabilities was $290.4 million in Q4 2025, with the low at $54.6 million in Q1 2023.
- The 5-year median for Total Current Liabilities is $105.3 million (2024), against an average of $133.0 million.
- Peak annual rise in Total Current Liabilities reached 132.08% in 2023, while the deepest fall reached 4.91% in 2023.
- Revolution Medicines' Total Current Liabilities stood at $62.0 million in 2022, then surged by 132.08% to $143.9 million in 2023, then gained by 13.95% to $163.9 million in 2024, then soared by 77.18% to $290.4 million in 2025, then slipped by 0.28% to $289.6 million in 2026.
- Business Quant data shows RVMD's Total Current Liabilities at $289.6 million in Q1 2026, $290.4 million in Q4 2025, and $245.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 283.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 354.06 Mn |
| Mar 31, 2026 | 289.60 Mn |
| Dec 31, 2025 | 290.42 Mn |
| Sep 30, 2025 | 245.62 Mn |
| Jun 30, 2025 | 184.53 Mn |
| Mar 31, 2025 | 158.60 Mn |
| Dec 31, 2024 | 163.91 Mn |
| Sep 30, 2024 | 110.86 Mn |
| Jun 30, 2024 | 105.33 Mn |
| Mar 31, 2024 | 93.72 Mn |
| Dec 31, 2023 | 143.85 Mn |
| Sep 30, 2023 | 85.54 Mn |
| Jun 30, 2023 | 78.06 Mn |
| Mar 31, 2023 | 54.64 Mn |
| Dec 31, 2022 | 61.98 Mn |
| Sep 30, 2022 | 73.27 Mn |
| Jun 30, 2022 | 63.54 Mn |
| Mar 31, 2022 | 57.46 Mn |
| Dec 31, 2021 | 60.35 Mn |
| Sep 30, 2021 | 51.89 Mn |